Want to see PTGX full AI Analyst Report?
PTGX Stock Chart & Stats
$105.98
-$0.87(-2.26%)
At close: 4:00 PM EST
$105.98
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$49.38 - $131.87
Previous CloseN/A
Volume120.35K
Average Volume (3M)603.88K
Market Cap
$8.46B
Enterprise Value$6.98B
Total Cash (Recent Filing)$547.79M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Jul 30, 2026EPS Estimate
2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding64,311,370
10 Day Avg. Volume725,496
30 Day Avg. Volume603,883
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue94.28
Enterprise Value/Gross Profit94.80
Enterprise Value/Ebitda-61.29
Forecast
1Y Price Target
$117.78Price Target Upside11.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.03
Revenue Forecast (FY)$503.79M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet; Very Low LeverageVery low leverage and substantial equity provide durable financial flexibility to fund multi-year clinical programs, absorb iterative R&D spend, and avoid near-term refinancing. That capital buffer supports sustained pipeline advancement and lowers solvency risk over the next 2–6 months.
High Gross Margins And Accelerating RevenueExceptionally high gross margins combined with significant topline acceleration imply strong unit economics for successful peptide candidates and improving commercial or partner monetization. This structural margin profile supports operating leverage as programs progress toward larger studies or partner triggers.
Governance Continuity And Incentive AlignmentBoard continuity, auditor ratification, and an equity incentive plan support stable oversight, financial controls, and employee/leadership retention. Those governance elements reduce execution risk and help maintain management focus on advancing the pipeline over the medium term.
Bears Say
Renewed Negative Operating And Free Cash FlowMaterial negative operating and free cash flow increases reliance on the balance sheet or new financing to sustain R&D and trials. Continued cash burn compresses runway and elevates funding risk, potentially forcing dilution or prioritized program cuts within months if trends persist.
Deep Operating Losses And Volatile ProfitabilityLarge, volatile losses reduce earnings quality and make multi-period planning harder; swings between profits and heavy losses indicate sensitivity to discrete events (licensing, one-time items) and raise uncertainty around sustainable margins and forecasting for partners or investors.
No Approved Products; Revenue Reliant On CollaborationsDependence on upfront, milestone and partner-funded R&D creates lumpy, event-driven revenue and ties cash flow to trial and partnership outcomes. Without commercial products, long-term cash generation remains contingent on successful development and partner execution.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics Inc’s price range in the past 12 months?
Protagonist Therapeutics Inc lowest stock price was $49.38 and its highest was $131.87 in the past 12 months.
What is Protagonist Therapeutics Inc’s market cap?
Protagonist Therapeutics Inc’s market cap is $8.46B.
When is Protagonist Therapeutics Inc’s upcoming earnings report date?
Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 27 days.
How were Protagonist Therapeutics Inc’s earnings last quarter?
Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.55.
Is Protagonist Therapeutics Inc overvalued?
According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued.
Does Protagonist Therapeutics Inc pay dividends?
Protagonist Therapeutics Inc does not currently pay dividends.
What is Protagonist Therapeutics Inc’s EPS estimate?
Protagonist Therapeutics Inc’s EPS estimate is 2.13.
How many shares outstanding does Protagonist Therapeutics Inc have?
Protagonist Therapeutics Inc has 64,311,370 shares outstanding.
What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?
Protagonist Therapeutics Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went up 4.798%.
Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.78 (11.13% Upside)
$117.78 (11.13% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 278.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.29%
12-Months-Change
Fundamentals
Return on Equity
-17.76%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$117.78
▲(11.13% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.19% Insiders
26.61% Mutual Funds
0.34% Other Institutional Investors
45.26% Public Companies and
Individual Investors